University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medicine and Radiology
  • Medicine and Radiology - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medicine and Radiology
  • Medicine and Radiology - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412

    Thumbnail
    Download
    Published version (1.397Mb)

    Citations
    Scopus
    Altmetric
    1
    Author
    Machiels, J-P; Tao, Y; Burtness, B; Tahara, M; Licitra, L; Rischin, D; Waldron, J; Simon, C; Gregoire, V; Harrington, K; ...
    Date
    2020-06-03
    Source Title
    Future Oncology
    Publisher
    FUTURE MEDICINE LTD
    University of Melbourne Author/s
    Rischin, Danny
    Affiliation
    Medicine and Radiology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Machiels, J. -P., Tao, Y., Burtness, B., Tahara, M., Licitra, L., Rischin, D., Waldron, J., Simon, C., Gregoire, V., Harrington, K., Alves, G. V., Lima, I. P. F., Pointreau, Y., Hughes, B. G. M., Aksoy, S., Hetnal, M., Ge, J. Y., Brown, H., Cheng, J. ,... Siu, L. L. (2020). Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. FUTURE ONCOLOGY, 16 (18), pp.1235-1243. https://doi.org/10.2217/fon-2020-0184.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/252429
    DOI
    10.2217/fon-2020-0184
    Abstract
    Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45689]
    • Medicine and Radiology - Research Publications [2346]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors